SIMULATED TREATMENT COMPARISON AND MATCHINGADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF EPLONTERSEN AND VUTRISIRAN FOR THE TREATMENT OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY

被引：0
|
作者：
Karam, C. [1 ]
Gillmore, J. D. [2 ]
Chen, G. [3 ]
Jenkins, N. C. [4 ]
Hale, M. J. [4 ]
Chen, J. [5 ]
Viney, N. J. [6 ]
Schneider, E. [6 ]
机构：
[1] Univ Penn, Dept Neurol, Philadelphia, PA USA
[2] UCL, Royal Free Hosp, Div Med, Natl Amyloidosis Ctr, London, England
[3] AstraZeneca, Cambridge, England
[4] Hlth Econ & Outcomes Res Ltd, Cardiff, Wales
[5] AstraZeneca, Gaithersburg, MD USA
[6] Ionis Pharmaceut Inc, Carlsbad, CA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO183
引用
收藏
页码：S46 / S47
页数：2
相关论文
共 50 条
  • [21] NEUROPATHY IMPAIRMENT AND NUTRITIONAL STATUS WITH EPLONTERSEN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS
    Conceicao, Isabel
    Wixner, Jonas
    Berk, John
    Adams, David
    Polydefkis, Michael
    Attarian, Shahram
    Gillmore, Julian
    Dyck, P. James
    Coelho, Teresa
    Chen, Jersey
    Hardy, Elise
    Kwoh, Jesse
    Natman, Jonatan
    Cruz, Marcia Waddington
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 : S138 - S138
  • [22] Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation
    Schmidt, Hartmut H.
    Wixner, Jonas
    Plante-Bordeneuve, Violaine
    Munoz-Beamud, Francisco
    Llado, Laura
    Gillmore, Julian D.
    Mazzeo, Anna
    Li, Xingyu
    Arum, Seth
    Jay, Patrick Y.
    Adams, David
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 (06) : 1646 - 1657
  • [23] Neuropathy impairment and nutritional status with eplontersen in patients with hereditary transthyretin-mediated amyloidosis
    Wixner, Jonas
    Conceicao, Isabel
    Berk, John
    Adams, David
    Polydefkis, Michael
    Shahram, Attarian
    Gillmore, Julian D.
    Dyck, P. James B.
    Coelho, Teresa
    Chen, Jersey
    Hardy, Elise
    Kwoh, Jesse
    Natman, Jonatan
    Cruz, Marcia Waddington
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S68 - S68
  • [24] HELIOS-A: RESULTS FROM THE PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY
    Gonzalez-Duarte, Alejandra
    Adams, David
    Tournev, Ivailo
    Taylor, Mark
    Coelho, Teresa
    Plante-Bordeneuve, Violaine
    Berk, John
    Gillmore, Julian David
    Low, Soon-Chai
    Sekijima, Yoshiki
    Obici, Laura
    Chen, Chongshu
    Badri, Prajakta
    Arum, Seth
    Vest, John
    Polydefkis, Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 302 - 302
  • [25] HELIOS-A: 9-MONTH RESULTS FROM THE RANDOMIZED TREATMENT EXTENSION PERIOD OF VUTRISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY
    Obici, Laura
    Polydefkis, Michael
    Gonzalez-Duarte, Alejandra
    Waddington-Cruz, Marcia
    Sekijima, Yoshiki
    Gillmore, Julian D.
    Yureneva, Elena
    Badri, Prajakta
    Chen, Chongshu
    Sweetser, Marianne
    Vest, John
    Adams, David
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2023, 28 : S40 - S40
  • [26] Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Labeyrie, Celine
    Merkel, Madeline
    Sethi, Sakshi
    Popadic, Lyuba
    Yang, Hongbo
    Sweetser, Marianne T.
    Lin, Hollis
    Adams, David
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (09)
  • [27] LONGTERM TREATMENT EFFECTS OF INOTERSEN ON QUALITY OF LIFE IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY
    Brown, Duncan
    Karam, Chafic
    Yang, Min
    Done, Nicolae
    Zhu, JingJing
    Greatsinger, Ali
    Bozas, Ana
    Llonch, Montserrat Vera
    Signorovitch, James
    MUSCLE & NERVE, 2021, 64 : S57 - S57
  • [28] Effect of RNAi therapeutics patisiran and vutrisiran on orthostatic hypotension due to dysautonomia in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Slama, M.
    Obici, L.
    Okumura, T.
    Arum, S.
    Hale, C.
    Jay, P. Y.
    Capocelli, K.
    Gonzalez-Duarte, A.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2625 - 2625
  • [29] Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform
    Conceicao, Isabel
    Berk, John L.
    Weiler, Markus
    Kowacs, Pedro A.
    Dasgupta, Noel R.
    Khella, Sami
    Chao, Chi-Chao
    Attarian, Shahram
    Kwoh, T. Jesse
    Jung, Shiangtung W.
    Chen, Jersey
    Viney, Nicholas J.
    Yu, Rosie Z.
    Gertz, Morie
    Masri, Ahmad
    Cruz, Marcia Waddington
    Coelho, Teresa
    JOURNAL OF NEUROLOGY, 2024, 271 (10) : 6655 - 6666
  • [30] Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis
    Kristen, Arnt, V
    Ajroud-Driss, Senda
    Conceicao, Isabel
    Gorevic, Peter
    Kyriakides, Theodoros
    Obici, Laura
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2019, 9 (01) : 5 - 24
12345